BR112023001307A2 - Combinação de inibidor de bcl-2 e agente hipometilante para tratamento de câncer, usos e composições farmacêuticas dos mesmos - Google Patents
Combinação de inibidor de bcl-2 e agente hipometilante para tratamento de câncer, usos e composições farmacêuticas dos mesmosInfo
- Publication number
- BR112023001307A2 BR112023001307A2 BR112023001307A BR112023001307A BR112023001307A2 BR 112023001307 A2 BR112023001307 A2 BR 112023001307A2 BR 112023001307 A BR112023001307 A BR 112023001307A BR 112023001307 A BR112023001307 A BR 112023001307A BR 112023001307 A2 BR112023001307 A2 BR 112023001307A2
- Authority
- BR
- Brazil
- Prior art keywords
- bcl
- inhibitor
- agent
- combination
- pharmaceutical compositions
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title abstract 4
- 229940123711 Bcl2 inhibitor Drugs 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 229940075628 hypomethylating agent Drugs 0.000 abstract 2
- VNNWQLOUMFCVJD-XIFFEERXSA-N 5-[5-chloro-2-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]phenyl]-N-(5-cyano-1,2-dimethylpyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2-dimethylpyrrole-3-carboxamide Chemical group Cc1c(cc(C#N)n1C)N(C(=O)c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n(C)c1C)c1ccc(O)cc1 VNNWQLOUMFCVJD-XIFFEERXSA-N 0.000 abstract 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical group O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 abstract 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 abstract 1
- GUWXKKAWLCENJA-WGWHJZDNSA-N [(2r,3s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2r,3s,5r)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)C1 GUWXKKAWLCENJA-WGWHJZDNSA-N 0.000 abstract 1
- 229960002756 azacitidine Drugs 0.000 abstract 1
- 229960003603 decitabine Drugs 0.000 abstract 1
- 229950001546 guadecitabine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
COMBINAÇÃO DE INIBIDOR DE BCL-2 E AGENTE HIPOMETILANTE PARA TRATAMENTO DE CÂNCER, USOS E COMPOSIÇÕES FARMACÊUTICAS DOS MESMOS. A presente invenção refere-se a uma combinação compreendendo um inibidor de Bcl-2 com um agente hipometilante, usos no trata-mento de cânceres e composições farmacêuticas do mesmo. O inibidor de Bcl-2 é 5-(5-cloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-di-hidroisoquinolin-2(1H)-il]carbonil}fenil)-N-(5-ciano-1,2-dimetil-1H-pirrol-3-il)-N-(4-hidroxifenil)-1,2-dimetil-1H-pirrol-3-carboxamida e o agente hipometilante é selecionado a partir de decitabina, azacitidina e guadecitabina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063059419P | 2020-07-31 | 2020-07-31 | |
| EP20195633 | 2020-09-11 | ||
| PCT/EP2021/071368 WO2022023514A1 (en) | 2020-07-31 | 2021-07-30 | Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023001307A2 true BR112023001307A2 (pt) | 2023-02-14 |
Family
ID=77595496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023001307A BR112023001307A2 (pt) | 2020-07-31 | 2021-07-30 | Combinação de inibidor de bcl-2 e agente hipometilante para tratamento de câncer, usos e composições farmacêuticas dos mesmos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230270748A1 (pt) |
| EP (1) | EP4188387A1 (pt) |
| JP (1) | JP2023537290A (pt) |
| KR (1) | KR20230044452A (pt) |
| CN (1) | CN116390735A (pt) |
| AU (1) | AU2021316674A1 (pt) |
| BR (1) | BR112023001307A2 (pt) |
| CA (1) | CA3190276A1 (pt) |
| CL (1) | CL2023000242A1 (pt) |
| CR (1) | CR20230046A (pt) |
| IL (1) | IL300145A (pt) |
| MX (1) | MX2023001335A (pt) |
| PH (1) | PH12023550205A1 (pt) |
| WO (1) | WO2022023514A1 (pt) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3008975A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| PL3873894T3 (pl) | 2018-10-31 | 2023-07-31 | Les Laboratoires Servier | Nowa sól inhibitora BCL-2, powiązana postać krystaliczna, sposób jej wytwarzania oraz zawierające ją kompozycje farmaceutyczne |
| UY38431A (es) | 2018-10-31 | 2020-05-29 | Servier Lab | Formulación basada en ciclodextrina de un inhibidor de bcl-2 |
-
2021
- 2021-07-30 CN CN202180066875.XA patent/CN116390735A/zh not_active Withdrawn
- 2021-07-30 MX MX2023001335A patent/MX2023001335A/es unknown
- 2021-07-30 JP JP2023505990A patent/JP2023537290A/ja not_active Withdrawn
- 2021-07-30 IL IL300145A patent/IL300145A/en unknown
- 2021-07-30 BR BR112023001307A patent/BR112023001307A2/pt unknown
- 2021-07-30 PH PH1/2023/550205A patent/PH12023550205A1/en unknown
- 2021-07-30 WO PCT/EP2021/071368 patent/WO2022023514A1/en not_active Application Discontinuation
- 2021-07-30 AU AU2021316674A patent/AU2021316674A1/en active Pending
- 2021-07-30 CA CA3190276A patent/CA3190276A1/en active Pending
- 2021-07-30 CR CR20230046A patent/CR20230046A/es unknown
- 2021-07-30 KR KR1020237006112A patent/KR20230044452A/ko active Pending
- 2021-07-30 EP EP21763238.9A patent/EP4188387A1/en active Pending
- 2021-07-30 US US18/007,321 patent/US20230270748A1/en active Pending
-
2023
- 2023-01-25 CL CL2023000242A patent/CL2023000242A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230270748A1 (en) | 2023-08-31 |
| CN116390735A (zh) | 2023-07-04 |
| CR20230046A (es) | 2023-04-11 |
| IL300145A (en) | 2023-03-01 |
| CL2023000242A1 (es) | 2023-11-10 |
| WO2022023514A1 (en) | 2022-02-03 |
| KR20230044452A (ko) | 2023-04-04 |
| CA3190276A1 (en) | 2022-02-03 |
| EP4188387A1 (en) | 2023-06-07 |
| MX2023001335A (es) | 2023-04-27 |
| AU2021316674A1 (en) | 2023-03-02 |
| JP2023537290A (ja) | 2023-08-31 |
| PH12023550205A1 (en) | 2024-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chu et al. | Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer | |
| Saygin et al. | Emerging therapies for acute myeloid leukemia | |
| Becker et al. | Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2 | |
| Durand et al. | Targeting reactive oxygen species in development and progression of pancreatic cancer | |
| Fredly et al. | Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents | |
| Miller et al. | Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors | |
| Sivaraj et al. | Panobinostat for the management of multiple myeloma | |
| Chen et al. | Nanoparticle-based drug delivery systems for targeted epigenetics cancer therapy | |
| Lim et al. | Molecular targeting in acute myeloid leukemia | |
| Daenen et al. | Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies | |
| Fiskus et al. | Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells | |
| Hurtubise et al. | Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells | |
| US20180042956A1 (en) | Glutamate Dehydrogenase 1 Inhibitors and Methods of Treating Cancer | |
| CL2021001018A1 (es) | Formulación basada en ciclodextrina de un inhibidor de bcl-2 | |
| Altucci et al. | Epigenetic therapies in haematological malignancies: searching for true targets | |
| De Schutter et al. | Radiosensitizing potential of epigenetic anticancer drugs | |
| Sebova et al. | Epigenetic tools in potential anticancer therapy | |
| Ahmad Ganai et al. | Plant derived inhibitor Sulforaphane in combinatorial therapy against therapeutically challenging Pancreatic Cancer | |
| BR112023001307A2 (pt) | Combinação de inibidor de bcl-2 e agente hipometilante para tratamento de câncer, usos e composições farmacêuticas dos mesmos | |
| Abbruzzese | Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality | |
| Zhong et al. | Preclinical evaluation of the HDAC inhibitor chidamide in transformed follicular lymphoma | |
| Park et al. | Beneficial effect of metronomic chemotherapy on tumor suppression and survival in a rat model of hepatocellular carcinoma with liver cirrhosis | |
| Friedmann et al. | Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer | |
| Lun et al. | Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy. | |
| Sweeney | Why cyclooxygenase-2 inhibition plus chemotherapy? |